Pliant Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for fibrotic diseases
The company is dedicated to discovering and advancing novel treatments that address the underlying mechanisms of tissue scarring and fibrosis across various organs. By leveraging its expertise in cellular and molecular biology, Pliant aims to transform the lives of patients suffering from debilitating conditions caused by excessive connective tissue growth, ultimately contributing to improved health outcomes and better quality of life.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen.
Shares of Air Products and Chemicals, Inc. (NYSEAPD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver fibrosis.
Keybanc cut the price target for Danaher Corporation (NYSEDHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market trading.
